A Multicenter Phase II Trial of Neoadjuvant Gefitinib Followed by Surgery, Followed by Adjuvant Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NEGOTIATE
- 19 Apr 2018 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.
- 19 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.
- 12 Apr 2016 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020, as reported by ClinicalTrials.gov.